TKO Group Holdings Inc (TKO) Stock Price Today
Aura AI Summary
Key Stats
- $14.60BMarket Cap
- -Volume
- TechnologySector
- $224.9652W High
- $176.4952W Low
- -Typical Hold Time
- $18.96BEnterprise Value
- 1.56%Div Yield
- -Trading Activity
Track TKO Group Holdings Inc (TKO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, TKO Group Holdings Inc has traded between a low of $176.49 and a high of $224.96, highlighting its annual price range. Buy and sell TKO Group Holdings Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Most Recent News
Definitive Healthcare posts a stellar 41.44% ROIC, far surpassing its 5.78% capital cost.
Definitive Healthcare Corp. stands out with a remarkable Return on Invested Capital (ROIC) of 41.44%, significantly exceeding its Weighted Average Cost of Capital (WACC) of 5.78%. This means the company generates over seven times the value for every ...

Abeona Therapeutics' price target cut to $15 after Q2 revenue miss and operational issues with Zevaskyn therapy.
Industrial Alliance Securities lowered Abeona Therapeutics' price target from $20 to $15 following a 14% stock drop after the company reported Q2 revenues of $11.4 million, missing analyst expectations. The company faces operational challenges with i...

Inovio advances DNA medicine pipeline with FDA review of INO-3107 and $18.3M funding secured
Inovio Pharmaceuticals is progressing its DNA medicine pipeline with its lead candidate INO-3107 for Recurrent Respiratory Papillomatosis under FDA accelerated review, targeting a decision by October 30, 2026. The company raised $18.3 million in fund...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.